Biogen Inc. (NASDAQ:BIIB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02
Mr.Capello is also entitled to receive continuation of medical and dental insurance benefits if severance is payable under the severance plan for Executive Vice Presidents.
| Item 5.02 | Regulation FD Disclosure. |
On November21, 2017, the Company issued a press release announcing the appointment of Mr.Capello as Executive Vice President and Chief Financial Officer of the Company effective as of December11, 2017. A copy of the press release is furnished as Exhibit 99.1 and is incorporated herein by reference.
The press release being furnished in this Item 5.02 shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall such document be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
| Item 5.02 | Financial Statements and Exhibits. |
(d)Exhibits
The exhibit listed on the Exhibit Index below is furnished as part of this Current Report on Form 8-K.
3
BIOGEN INC. ExhibitEX-99.1 2 d281870dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 MEDIA CONTACT: Biogen Matt Fearer Ph: +1 781 464 3260 [email protected] INVESTOR CONTACT: Biogen Matt Calistri Ph: +1 781 464 2442 [email protected] BIOGEN APPOINTS JEFF CAPELLO AS EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER CAMBRIDGE,…To view the full exhibit click here
About Biogen Inc. (NASDAQ:BIIB)
Biogen Inc., formerly Biogen Idec Inc., is a biopharmaceutical company. The Company operates in discovering, developing, manufacturing and delivering therapies to patients for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders segment. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for multiple sclerosis (MS), ELOCTATE for hemophilia A and ALPROLIX for hemophilia B, and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc., a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other potential anti-CD20 therapies. It also develops late stage product candidates, including Aducanumab (BIIB037) for the treatment of Neurodegeneration, and Nusinersen for other programs.
